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Introduction
Afflicting more than 60 million individuals worldwide and leav-
ing 8 million blind, glaucoma is a devastating disease with no cure 
(1). Current therapy slows disease progression but cannot repair 
the damage to retinal ganglion cells — underscoring the urgent 
unmet need for new drug targets and treatments. Elevated intra-
ocular pressure (IOP) is an important risk factor for glaucoma, and 
patients with high-pressure glaucoma exhibit defects in aqueous 
humor drainage from the anterior chamber (2, 3). Aqueous humor 
is secreted by the ciliary body before entering the anterior cham-
ber, where it is drained through outflow structures in the irido-
corneal angle. Decreased flow through these pathways creates an 
imbalance in fluid homeostasis, leading to ocular hypertension 
and glaucoma. In humans, the majority of aqueous humor out-
flow is carried out through the conventional route, composed of 
the trabecular meshwork (TM) and Schlemm’s canal (SC), a large, 
hybrid vessel with lymphatic and venous features located within 
the iridocorneal angle (4–6). Despite the central role of SC in IOP 
maintenance and disease, no pharmacological tools targeting 
the canal are currently available in the clinic. Recently, however, 
the importance of endothelial growth factor signaling has been 
appreciated, and critical roles for both the VEGF/VEGFR and the 
ANGPT/TEK pathway have been described (5–8), identifying an 
array of potential targets for future therapeutic development.
The angiopoietin (ANGPT)/TEK (tunica interna endothelial 
cell kinase, also known as TIE2) signaling pathway is composed 
of 3 ligands (ANGPT1, ANGPT2, and ANGPT4) and 2 receptors 
(TEK and TIE) (9, 10). Loss-of-function mutations in the endo-
thelial receptor tyrosine kinase TEK, which is highly expressed 
Primary congenital glaucoma (PCG) is a leading cause of blindness in children worldwide and is caused by developmental 
defects in 2 aqueous humor outflow structures, Schlemm’s canal (SC) and the trabecular meshwork. We previously 
identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed that 
ANGPT/TEK signaling is essential for SC development. Here, we describe roles for the major ANGPT ligands in the 
development of the aqueous outflow pathway. We determined that ANGPT1 is essential for SC development, and that 
Angpt1-knockout mice form a severely hypomorphic canal with elevated intraocular pressure. By contrast, ANGPT2 
was dispensable, although mice deficient in both Angpt1 and Angpt2 completely lacked SC, indicating that ANGPT2 
compensates for the loss of ANGPT1. In addition, we identified 3 human subjects with rare ANGPT1 variants within 
an international cohort of 284 PCG patients. Loss of function in 2 of the 3 patient alleles was observed by functional 
analysis of ANGPT1 variants in a combined in silico, in vitro, and in vivo approach, supporting a causative role for ANGPT1 
in disease. By linking ANGPT1 with PCG, these results highlight the importance of ANGPT/TEK signaling in glaucoma 
pathogenesis and identify a candidate target for therapeutic development.
Angiopoietin-1 is required for Schlemm’s canal 
development in mice and humans
Benjamin R. Thomson,1,2 Tomokazu Souma,1,2 Stuart W. Tompson,3 Tuncer Onay,1,2 Krishnakumar Kizhatil,4 Owen M. Siggs,5 
Liang Feng,6 Kristina N. Whisenhunt,3 Tammy L. Yanovitch,7 Luba Kalaydjieva,8 Dimitar N. Azmanov,8,9 Simone Finzi,10  
Christine E. Tanna,1,2 Alex W. Hewitt,11,12,13 David A. Mackey,12,13 Yasmin S. Bradfield,3 Emmanuelle Souzeau,5  
Shari Javadiyan,5 Janey L. Wiggs,14 Francesca Pasutto,15 Xiaorong Liu,6 Simon W.M. John,4 Jamie E. Craig,5  
Jing Jin,1,2 Terri L. Young,3 and Susan E. Quaggin1,2
1Feinberg Cardiovascular Research Institute and 2Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 3Department of Ophthalmology and 
Visual Sciences, University of Wisconsin–Madison, Madison, Wisconsin, USA. 4Howard Hughes Medical Institute and The Jackson Laboratory, Bar Harbor, Maine, USA. 5Department of Ophthalmology, 
Flinders University, Adelaide, South Australia, Australia. 6Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 7Department of Ophthalmology,  
Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma, USA. 8Harry Perkins Institute of Medical Research and Centre for Medical Research, University of Western Australia, Perth, 
Western Australia, Australia. 9Department of Diagnostic Genomics, PathWest, QEII Medical Centre, Perth, Western Australia, Australia. 10Department of Ophthalmology, Hospital das Clínicas of University  
of São Paulo, São Paulo, Brazil. 11Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia. 12Centre for Ophthalmology and Visual 
Science, University of Western Australia, Lions Eye Institute, Perth, Western Australia, Australia. 13Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.  
14Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA. 15Institute of Human Genetics, Friedrich-Alexander-Universität  
Erlangen-Nürnberg, Erlangen, Germany.
Authorship note: B.R. Thomson and T. Souma contributed equally to this work. T.L. Young 
and S.E. Quaggin contributed equally to this work.
Conflict of interest: S.E. Quaggin holds patents (US patent US9719135B2) related to 
therapeutic targeting of the ANGPT/TEK pathway in ocular hypertension and glaucoma 
and receives research support from, owns stock in, and is a director of Mannin Research.
Submitted: June 12, 2017; Accepted: September 26, 2017.
Reference information: J Clin Invest. https://doi.org/10.1172/JCI95545.
Downloaded from http://www.jci.org on November 28, 2017.   https://doi.org/10.1172/JCI95545
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 jci.org
Results
Angpt1 and Angpt2 are expressed in the iridocorneal angle. To better 
understand the role of each ANGPT ligand in SC development and 
function, we analyzed their expression pattern in the limbus using 
Angpt1GFP and Angpt2LacZ reporter mice. Angpt1 is expressed in the 
TM and in cells adjacent to the SC outer wall, although no expres-
sion is seen in the endomucin-positive SC endothelium (Figure 
1A). Conversely, Angpt2 is expressed by the SC endothelium, as 
well as by endothelial cells of limbal capillaries and the corneal 
endothelium (Figure 1B).
ANGPT1 is the primary TEK ligand in the iridocorneal angle. 
As both Angpt1 and Angpt2 are highly expressed in the iridocor-
neal angle, we used a knockout mouse approach to discover a 
specific role(s) for each ligand in canal formation. Mice lack-
ing Angpt1, Angpt2, or both Angpt1 and Angpt2 after embryonic 
day 16.5 (WBΔE16.5) were generated using a doxycycline-based 
conditional gene targeting strategy as previously described (7). 
Lacking suitable antibodies for Western blot, knockout was con-
firmed using real-time PCR (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI95545DS1). While control mice exhibit a continuous CD31-pos-
itive SC, confocal microscopy revealed complete absence of SC in 
Angpt1;Angpt2 double-knockout mice (Angpt1;Angpt2WBΔE16.5) (Fig-
ure 1C). Similarly, Angpt1WBΔE16.5 mice exhibited a severely hypo-
plastic SC phenotype characterized by gaps and discontinuous, 
isolated canal segments. While this phenotype was less severe than 
in the SC endothelium (5), have been identified in patients with 
primary congenital glaucoma (PCG), an especially devastating 
form of the disease characterized by infant/early-childhood 
onset, buphthalmos, and optic neuropathy (8). In mice, loss of 
TEK signaling through either deletion of both primary ANGPT 
ligands or deletion of the TEK receptor results in failure of SC 
development and rapidly progressing ocular hypertension (7, 
8). However, while the importance of ANGPT/TEK signaling in 
canal development and associated aqueous humor drainage is 
clear, the individual roles for each of the major ANGPT ligands 
are not understood.
Outside of the iridocorneal angle, ANGPT1 is expressed by 
pericytes and other vascular supporting cells, but not in the endo-
thelium (11). It has been described as the primary TEK agonist, 
activating the receptor to drive its proangiogenic and vessel sta-
bilizing activity (9, 12, 13). The other major ligand, ANGPT2, is a 
context-dependent agonist/antagonist of TEK signaling secret-
ed by the endothelium as well as vascular supporting cells in 
specific vascular beds such as the renal mesangium and smooth 
muscle cells (9, 13–16).
Here, we describe the individual roles of ANGPT1 and 
ANGPT2 in SC development and identify ANGPT1 as the primary 
TEK ligand in canal formation. Furthermore, we have identified 
and characterized human ANGPT1 loss-of-function mutations in 
a PCG cohort of 284 families that did not harbor mutations in the 
known PCG-causing genes CYP1B1 or TEK.
Figure 1. ANGPT1 is the primary TEK ligand in SC development. (A) Localization of Angpt1 expression in the limbal region. Cryosections from adult Angpt1GFP 
knockin mice show strong GFP expression in the TM and cells adjacent to the SC outer wall. Endomucin staining outlines the SC endothelium and capillar-
ies of the superficial vascular plexus (SVP). (B) Angpt2 expression in the anterior chamber. Paraffin sections from adult X-gal–stained Angpt2LacZ knock-in 
mice show X-gal staining in the SC and corneal endothelium, as well as capillaries of the SVP. (C) In comparison with control littermates, eyes from mice 
with defective angiopoietin signaling failed to develop a normal SC. As previously described, Angpt1 Angpt2 double-knockout (Angpt1;2) mice completely 
lacked SC. Interestingly, however, while Angpt1WBΔE16.5 mice exhibited a severely hypoplastic canal with only focal development, Angpt2WBΔE16.5 mice had no 
apparent defect. (D) IOP measurements showed similar results (Angpt1 Angpt2 n = 12, control n = 42; Angpt1 n = 7, control n = 14; Angpt2 n = 3, control  
n = 4). This highlights the role of ANGPT1 as the major TEK ligand in canal development, though it suggests the possibility of limited compensation. Red 
arrows in C highlight SC. White arrows indicate the direction of the cornea. Note that faint staining in Angpt1;2 and Angpt1 knockout panels is out of focus 
light from the ciliary body and limbal vascular plexus. Scale bars: 50 μm (A and B) and 250 μm (C). ***P ≤ 0.001 as determined by Welch’s t test.
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sure (Angpt1WBΔE16.5, 23.53 ± 1.50 mmHg; controls, 14.29 ± 0.92 
mmHg; P = 0.0004). Notably, despite the difference between 
Angpt1;Angpt2 and Angpt1 knockouts, Angpt2-knockout mice 
exhibited normal IOP (Angpt2WBΔE16.5, 15.13 ± 0.41; control, 14.94 ± 
1.01; P = 0.882), supporting the dispensable role of ANGPT2 in SC 
development and function.
ANGPT1 is required for development of SC and the TM. Our find-
ings showed that ANGPT1 is a critical regulator of SC morphology 
and function, but did not distinguish between developmental and 
that observed in Angpt1;Angpt2 double knockouts, a clear require-
ment for ANGPT1 was observed. In contrast, SC had no apparent 
morphological defects in Angpt2-knockout mice. To determine the 
consequence of these SC defects for aqueous humor homeostasis, 
IOP was measured in Angpt1, Angpt2, and Angpt1;Angpt2-knock-
out mice at 8 weeks of age (Figure 1D). Angpt1;Angpt2WBΔE16.5 mice 
presented with dramatic IOP elevation (Angpt1;Angpt2WBΔE16.5, 
35.58 ± 2.01 mmHg; controls, 15.45 ± 0.72; P < 0.0001). By con-
trast, Angpt1 knockouts exhibited only moderately elevated pres-
Figure 2. ANGPT1 is essential for SC formation. SC development and maturation in Angpt1-knockout mice. Compared with littermate controls, SC devel-
opment was disrupted in Angpt1WBΔE16.5 mice. Fewer CD31-positive sprouts emerge from the limbal capillaries, and these sprouts failed to consolidate and 
proliferate into a cohesive SC. In addition, PROX1 expression was dramatically reduced in the disorganized SC plexus of mutant mice, indicating that these 
cells failed to differentiate into the mature SC cell fate. Dashed lines in PROX1 panels highlight the CD31-positive sprout and SC area from matching CD31 
staining. Littermate controls were used for all time points; eyes from 3 knockout and 3 control mice (P1, P12), 4 knockouts and 4 controls (P4), 6 knockouts 
and 5 controls (P7), 4 knockouts and 5 controls (P14), and 4 knockouts and 3 controls (P21) were analyzed. Three fields were captured per eye, and the 
results were averaged. AFU, background subtracted arbitrary fluorescence units. Scale bars: 50 μm; ×20 fields comprise an area of 65,536 μm2. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001 as determined by Student’s t test.
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eration required to overcome this handicap and form a complete 
canal (Supplemental Figure 4). In control mice, between P4 and P7, 
SC endothelial cells began to differentiate into a clear SC cell fate, 
expressing the lymphatic marker PROX1 (Figure 2). However, this 
differentiation did not take place in the vestigial canal structure 
observed in knockout mice, and PROX1 expression remained low. 
By adulthood, only isolated segments of canal endothelium were 
observed in knockout mice. Importantly, each of these remaining 
segments was connected to the limbal blood vascular plexus by at 
least 1 drainage channel, suggesting that the residual SC fragments 
may retain some function (Supplemental Figure 5).
To examine the effect of Angpt1 deletion on TM development, 
plastic semithin sections were prepared from the iridocorneal 
region and stained with H&E. While control littermates showed a 
well-developed SC and TM, Angpt1WBΔE16.5 mice exhibited a small 
or absent SC associated with a severely hypoplastic TM (Fig-
ure 3A). Immunofluorescent staining using an antibody against 
α-smooth muscle actin, which specifically labels the ciliary muscle 
and TM, highlighted this TM defect (Figure 3B).
degenerative phenotypes. To determine the role of ANGPT1 in canal 
development, eyes were collected at intervals from birth to P21 and 
canal morphology was observed by confocal microscopy. SC forms 
in the postnatal period from sprouts that branch off the limbal vas-
cular plexus (LVP); at P1, the LVPs of Angpt1WBΔE16.5 eyes were found 
to have significantly reduced pre-SC endothelial sprouting in com-
parison with control littermates, in both total area (Figure 2) and 
sprout number (Supplemental Figure 2). Interestingly, the LVP area 
appeared normal in Angpt1WBΔE16.5 mice, which suggested that these 
sprouting defects were unique to SC development and were not due 
to a failure in LVP capillary or global endothelial sprouting (Supple-
mental Figure 3). By P4, the difference between mutant and control 
SC became more pronounced. At this time point, consolidation of 
sprouting endothelial cells into a canal-like structure was apparent 
in control mice, whereas in Angpt1WBΔE16.5 littermates the endothelial 
cells remained disorganized with no apparent canal structure (Fig-
ure 2). This trend continued throughout development as, compared 
with controls, knockout mice began with a smaller pool of sprout-
ing SC progenitor cells and never exhibited the increased prolif-
Figure 3. SC and the TM are 
defective in Angpt1WBΔE16.5 mice. 
(A) Iridocorneal angle region from 
control and Angpt1WBΔE16.5 mouse 
eyes obtained after imaging of 
plastic sections of eyes stained 
with H&E. Top panels show the 
location of SC and the TM within 
the iridocorneal angle. Magnified 
images of the region within the 
dotted box in the top panels are 
shown below for each panel. The 
control showed a well-developed 
SC and TM in contrast to mutants, 
in which the TM was hypoplastic 
and the SC was either absent or 
severely reduced in size. Control  
n = 4, Angpt1WBΔE16.5 n = 8. Scale 
bars: top panels, 50 μm, and bot-
tom panels, 10 μm. (B) α-Smooth 
muscle actin–stained (α-SMA–
stained) sections of the iridocor-
neal angle region from control and 
Angpt1WBΔE16.5 eyes, showing the 
ciliary muscle (CM) and TM. SC is 
indicated by a dashed oval. As in 
A, eyes lacking Angpt1 showed 
dramatic reduction in the size of 
SC and associated TM. Scale bar: 
250 μm.
Figure 4. Angpt1-knockout mice exhibit clinical signs of glaucoma. 
(A) Intraocular pressure (IOP) of Angpt1-knockout mice. Compared 
with control littermates, Angpt1WBΔE16.5 mice rapidly developed elevated 
IOP. Angpt1WBΔE16.5 n = 7, control n = 13. (B) Measurement of retinal gan-
glion cell number. When dissected at 19 weeks, mice lacking Angpt1 
exhibited significant reductions in retinal ganglion cells compared 
with littermate controls. Angpt1WBΔE16.5 n = 5, control n = 4. **P ≤ 0.01, 
***P ≤ 0.001 as determined by 2-way ANOVA followed by Bonferroni’s 
correction (A) or Student’s t test (B).
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tribute to glaucoma pathogenesis in humans. To investigate this 
possibility, the ANGPT1 gene was sequenced in a cohort of 284 
PCG families with no mutations in the most commonly mutated 
PCG genes, including CYP1B1 and TEK. Of this cohort, exome 
sequence data were available for 135 families, while direct Sanger 
sequencing of the ANGPT1 gene was performed on the remain-
ing 149. In addition to CYP1B1 and TEK, exome-sequenced cases 
were also screened for rare PCG-associated mutations in LTBP2, 
FOXC1, and MYOC as well as novel, PCG-associated mutations 
in ANGPT2 and ANGPT4. Variant data were filtered to remove 
synonymous changes, intronic variants more than 10 nucleotides 
from the intron-exon splice site junctions, variants present in the 
Exome Aggregation Consortium (ExAC) public database (exac.
broadinstitute.org) at an allele frequency greater than 0.0001, and 
variants identified in an in-house database of 120 control exomes. 
The remaining variants identified through exome sequencing 
were validated by Sanger sequencing.
Heterozygosity for 2 novel nonsense variants (p.Q236*, 
p.R494*) and 1 rare missense variant (p.K249R) was identified 
in ANGPT1 in 3 PCG families (Figure 5A and Table 1), while no 
novel PCG-associated variants were identified in ANGPT2 or 
ANGPT4. In humans, the ANGPT1 gene encodes a principal pro-
tein product of 498 amino acids in 9 exons. Each of the patient 
variants identified was predicted to affect this protein product in 
markedly different ways (Figure 5B). p.Q236* introduced a stop 
codon prematurely within exon 4 of the mRNA transcript. Trun-
cated transcripts produced by this variant allele are expected to be 
recognized by the nonsense-mediated decay (NMD) pathway and 
eliminated. Any transcripts that are translated into protein would 
Angpt1-knockout mice develop a glaucoma-like phenotype. 
To determine the link between SC development and anterior 
chamber drainage, IOP was measured over time in a cohort of 7 
Angpt1WBΔE16.5 and 13 control mice (Figure 4A). While the initial 
measurement at 4 weeks showed no difference in IOP, subsequent 
measurements at 8 and 12 weeks revealed a marked IOP eleva-
tion in Angpt1WBΔE16.5 mice (8 weeks: Angpt1WBΔE16.5, 23.53 ± 1.50; 
control, 14.29 ± 0.92; P < 0.001; 12 weeks: Angpt1WBΔE16.5, 24.143 
± 1.06; control, 17.55 ± 1.16; P < 0.001). As elevated IOP is strong-
ly correlated with glaucoma pathogenesis, we next performed a 
series of studies to look for signs of glaucoma in a second cohort 
of Angpt1WBΔE16.5 mice. Retinal ganglion cells (RGCs) were exam-
ined by immunohistochemistry, using antibodies against BRN3A 
and BRN3B, markers specific for RGCs. At 19 weeks, knockout 
mice had reductions in BRN3A-labeled RGC counts compared 
with their WT control littermates (Figure 4B; Angpt1WBΔE16.5, 22.38 
± 0.30; control, 25.09 ± 0.28; P = 0.0003). Similar reductions were 
found in BRN3B cell density (Angpt1WBΔE16.5, 15.57 ± 0.58; control, 
18.35 ± 0.29; P = 0.0053). Taken together these results are con-
sistent with glaucomatous neurodegeneration, although further 
studies will be required to fully characterize the glaucoma pheno-
type in Angpt1WBΔE16.5 mice.
Loss-of-function mutations in ANGPT1 are associated with 
human PCG. SC defects observed in Angpt1WBΔE16.5 mice, includ-
ing narrowing, gaps, and rarefication of the TM, resemble a more 
severe form of the phenotypes previously described in mice het-
erozygous for the gene encoding the ANGPT1 receptor TEK. This 
similarity between mouse phenotypes suggested that, like muta-
tions in TEK, loss-of-function mutations in ANGPT1 may con-
Figure 5. Pedigrees and ANGPT1 variants identified in 3 families. (A) Pedigrees of 3 families with ANGPT1 mutations. Specific mutations in ANGPT1 are 
listed below the different pedigrees, with carrier family members annotated as +/M. Affected individuals are indicated by solid black symbols. Note: White 
symbols do not exclude an undiagnosed late-onset disease. Parental genotypes/phenotypes are unknown for family 3. (B) Schematic representation of 
ANGPT1 protein domains and identified mutations in this study. S, signal peptide; SCD, superclustering domain; CCD, coiled-coil domain; L, linker domain; 
FLD, fibrinogen-like domain. (C) Sequence alignment of ANGPT1  K249 showing strong evolutionary conservation.
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result in a truncated product containing the N-terminal oligomer-
ization domain, but lacking the full C-terminal receptor binding 
domain that is essential for interaction with the TEK receptor. 
Conversely, the p.R494* variant introduces a stop codon just 5 
residues prior to the normal termination codon in exon 9, and will 
likely escape NMD as premature truncations located in the final 
exon do not induce this mRNA cleanup system (17). The result-
ing protein product would contain the complete oligomerization 
domain, but lack the terminal 5 amino acids of the receptor bind-
ing domain. While ANGPT1R494* may be capable of interacting 
with the TEK receptor, these 5 amino acids are highly conserved 
throughout vertebrate evolution (Supplemental Figure 6), and 
their deletion was predicted by FoldX to strongly destabilize the 
protein (FoldX score 5.36).
Unlike the 2 nonsense variants, the p.K249R missense variant 
was predicted to be tolerated by SIFT (sift.jcvi.org) and FATHMM 
(fathmm.biocompute.org.uk) with no expected effect on protein 
function. However, K249 is evolutionarily well conserved (Figure 
5C), and this mutation has been observed only once (in a South 
Asian individual) out of more than 121,000 alleles in the ExAC 
database. Owing to the location of this modified amino acid, we 
predicted that ANGPT1K249R might be unable to properly oligomer-
ize, which is important for its ability to activate TEK (18–20).
To determine whether these variant ANGPT1 proteins have 
a reduced ability to activate TEK signaling, we generated heter-
ologous expression vectors for WT and variant ANGPT1 proteins 
in cell culture models (Supplemental Figure 7) and performed in 
vitro assays to examine expression, intracellular trafficking, and 
signaling function. In vivo, WT ANGPT1 is a soluble growth factor 
secreted by pericytes, podocytes, and other vascular support cells. 
When heterologously expressed in HEK293 cells, WT ANGPT1 
was produced and readily secreted into the growth medium, 
where it was detected using a C-terminal FLAG tag as previously 
reported (ANGPT1-FLAG; Figure 6A and ref. 18).
By SDS-PAGE, ANGPT1-FLAG monomers were found to run 
at approximately 75 kDa (Figure 6A). However, under nonreducing 
conditions, WT ANGPT1 protein was predominantly grouped in 
high-order multimers of greater than 250 kDa, consistent with earli-
er reports (18, 21). A similar multimerization pattern was observed in 
ANGPT1K249R-FLAG variant protein, which was robustly expressed 
and secreted into the cell medium. Unlike the missense K249R 
variant, ANGPT1Q236*-FLAG contains a premature stop codon 
upstream of the expression vector FLAG tag (Supplemental Fig-
ure 7B). As expected, this stop codon prevented production of full-
length FLAG-labeled mutant protein, and none was observed in the 
media (Figure 6A), although unlabeled, truncated protein product 
may have been produced. Unlike the ANGPT1Q236*-FLAG construct, 
the tagged ANGPT1R494* construct was designed by insertion of the 
FLAG tag directly following I493 to create ANGPT1R494_F498del-FLAG. 
Interestingly, no secreted ANGPT1R494_F498del-FLAG protein could 
be detected following transfection in HEK293 cells. This was sur-
prising given the location of the mutation in the C-terminal fibrin-
ogen domain, and we had not anticipated a defect in secretion. We 
hypothesized that this mutant protein may be trapped within the cell 
or subject to premature degradation.
To test the ability of each ANGPT1 variant protein to activate 
TEK and initiate a downstream signaling cascade, conditioned 
medium from transfected HEK293 cells was used to stimulate 
primary HUVECs, which express TEK (Figure 6B). Consistent 
with the expression and oligomerization data, conditioned media 
from WT ANGPT1- and ANGPT1K249R-expressing cells potently 
induced AKT phosphorylation, while media from ANGPT1Q236*- or 
ANGPT1R494*-expressing cells did not.
As ANGPT1K249R was expressed and activated pAKT signaling 
normally, we used a pulldown approach to test its ability to interact 
with TEK (Figure 6C). Conditioned medium from HEK293 cells 
transfected with WT ANGPT1-FLAG or ANGPT1K249R-FLAG was 
incubated with recombinant human TEK-Fc fusion protein com-
prising the TEK extracellular domain (Ala23-Lys745) tagged with 
a human IgG Fc sequence. Both WT ANGPT1 and ANGPT1K249R 
were found to strongly bind TEK-Fc, confirming the ability of this 
variant protein to interact with its receptor.
The p.Q236* mutant cDNA did not produce a full-length intact 
protein with C-terminal FLAG tag, as the introduced stop codon is 
upstream of the tag sequence (Figure 6A and Supplemental Fig-
ure 7B). Therefore, to further analyze the function of the predicted 
protein product resulting from the p.Q236* mutation, we gener-
ated an additional ANGPT1Q236_F498del-HA expression construct in 
which the HA tag was added in frame directly to the 3′ end of the 
predicted short ANGPT1Q236* (M1-K235) protein. As ANGPT1Q236* 
contains the intact ANGPT1 oligomerization domain (Figure 5B), 
we then performed immunoprecipitation assays to determine the 
Table 1. ANGPT1 variants identified in PCG families
ExAC


















1 c.1480C>T p.R494* 108264100 9 2 yr 41 yr N/A M Eur (Am) NovelA 121,306 66,690
2 c.706C>T p.Q236* 108334226 4 Birth N/A 2 F Eur (Au) NovelB 121,360 66,718
3 c.746A>G p.K249R 108334186 4 Birth N/A 2 M Afr (Au) 1 (SA) 121,376 10,406
Ethnicities: Eur, European; Afr, African; Am, American; Au, Australian; SA, South Asian. ExAC, Exome Aggregation Consortium database; N/A, data not 
available. Carrier age, age of unaffected mutation carrier at time of last eye exam. Chromosome position is listed in accordance with the human GRCh37/
hg19 reference assembly. Coding DNA mutation is in relation to ANGPT1 mRNA reference sequence NM_001146.3. Protein change is in relation to ANGPT1 
protein reference sequence NP_001137.2. Ac.1480C>T is a known variant (rs144684252) in the National Heart, Lung, and Blood Institute Exome Sequencing 
Project (ESP) data set, identified in 1 of 8,600 European alleles. Bc.706C>T was identified in a single in-house Australian control sample.
Downloaded from http://www.jci.org on November 28, 2017.   https://doi.org/10.1172/JCI95545
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
7jci.org
ability of this variant to oligomerize with WT ANGPT1 (Figure 6D). 
When coexpressed in HEK293 cells, ANGPT1Q236_F498del-HA was 
found to robustly interact with WT ANGPT1. Although we expect 
the majority of Angpt1p.Q236* transcripts to be degraded by NMD, 
these results suggested that any ANGPT1Q236* mutant protein that 
escapes NMD and is produced might act in a dominant-negative 
fashion by oligomerizing with WT ANGPT1 — diminishing TEK 
activation by forming ANGPT1 multimers with fewer receptor 
binding domains.
To exclude the possibility that protein trafficking or secre-
tion defects we observed in cells transfected with ANGPT1R494* 
were the result of expression tag addition, HEK293 cells were 
transfected with untagged WT Angpt1 or Angpt1p.R494*, and the 
conditioned media and cell lysates were subjected to SDS-PAGE 
(Figure 6, E and F). While WT ANGPT1 protein was observed in 
the cell media, ANGPT1R494* was detected only in the cell lysate. 
Incubation with the proteasome inhibitor MG132 increased the 
abundance of both WT and mutant ANGPT1 within the cell, but 
had no effect on the secretion of mutant protein into the media. 
When observed by immunocytochemistry in transfected NIH 
3T3 cells, WT ANGPT1 was distributed throughout the cell, only 
partially colocalized with an ER marker, protein disulfide isom-
erase (PDI; Figure 7A, top panel). However, unlike the uniform 
distribution of WT ANGPT1, ANGPT1R494* was observed only in 
large vacuole-like structures that were colocalized with PDI (Fig-
ure 7A, bottom panel) but not Golgin-97 (a marker of the Golgi 
apparatus; Figure 7B). Taken together, these results suggested 
that ANGPT1R494* was trapped within ER-derived vesicles and 
not secreted from the cell.
To determine whether ANGPT1R494*, like ANGPT1Q236*, could 
interact with WT ANGPT1 and act in a dominant-negative fash-
ion, or whether the presence of WT ANGPT1 could aid in traffick-
ing of the mutant protein, we cotransfected NIH 3T3 cells with 
WT ANGPT1-FLAG and untagged WT ANGPT1 or ANGPT1R494*. 
Immunocytochemistry using anti-FLAG antibody revealed WT 
ANGPT1-FLAG in large intracellular vesicles when coexpressed 
with ANGPT1R494*, but not with WT ANGPT1 (Figure 7B), suggest-
ing that the mutant protein could interact with WT ANGPT1.
Generation and analysis of ANGPT1p.R494* mutant mice. In vitro, 
ANGPT1R494* was not secreted and was instead found aggregat-
ed in ER-derived vesicles — consistent with our in silico analysis 
predicting that this variant would produce a strongly destabi-
Figure 6. Expression and multimerization 
pattern of ANGPT1 variants. (A) Western blot of 
FLAG-tagged WT and variant ANGPT1 proteins 
secreted by transfected HEK293 cells. Under 
nonreducing conditions WT and ANGPT1K249R 
(K249R-FLAG) were observed in high-order oligo-
mers. The premature stop codon upstream of the 
FLAG tag in ANGPT1Q236* (Q236*-FLAG) prevented 
production of full-length, FLAG-tagged protein. 
Surprisingly, however, despite the insertion of 
the FLAG tag upstream of the premature stop 
codon in ANGPT1R494* (R494_F498del-FLAG), 
no tagged protein was detected in the culture 
medium. (B) Western blot of HUVECs incubat-
ed with conditioned media from transfected 
HEK293 cells. Conditioned media from cells 
expressing WT ANGPT1 and ANGPT1K249R strongly 
induced AKT phosphorylation, while media from 
cells expressing ANGPT1Q236* and ANGPT1R494* 
did not. (C) Conditioned medium from HEK293 
cells transfected with WT ANGPT1-FLAG or 
ANGPTK249R-FLAG was incubated with recombi-
nant human TEK-Fc fusion protein to test the 
receptor-binding ability of this variant protein. 
(D) When coexpressed, FLAG-tagged WT ANGPT1 
strongly pulled down ANGPT1Q236* with an HA tag 
inserted upstream of the premature stop codon 
(Q236_F498del-HA), indicating an interaction 
and potential dominant-negative activity. (E and 
F) Untagged WT and R494* variant ANGPT1 was 
expressed in HEK293 cells and immunoblotted 
using anti-ANGPT1 antibody. Only WT protein 
was detected in the conditioned medium, 
while ANGPT1R494* appears to be expressed but 
retained in the intracellular compartment. MG132 
treatment was performed to block the protea-
somal pathway. Coomassie blue staining and 
anti-tubulin (Tub) immunoblotting were used as 
loading controls for the conditioned media and 
cell lysate, respectively.
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8E). This finding was consistent with the normal IOP observed in 
adult Angpt1Null/WT heterozygous mice (Supplemental Figure 10).
Although the Angpt1p.R494* allele did not affect SC development 
in the heterozygous state, this lack of phenotype was shared by the 
Angpt1 heterozygotes. Therefore, we set out to determine whether 
Angpt1p.R494* serves as a functional null allele in the absence of WT 
ANGPT1. As homozygous Angpt1Null mice die between E9.5 and 
E12.5 (11, 12), an Angpt1p.R494*/WT heterozygous male mouse was 
crossed to Angpt1Null/WT and Angpt1p.R494*/WT females to generate lit-
ters of Angpt1p.R494*/Null compound mutants and Angpt1
p.R494* homo-
zygotes (Figure 9A). Strikingly, while Angpt1p.R494*/Null compound 
mutants were observed at E10.5 at normal Mendelian ratios (Fig-
ure 9A), no Angpt1p.R494*/Null compound mutants or Angpt1p.R494*/p.R494* 
homozygotes were found alive by E12.5, and no mutants were 
observed in litters collected after birth — demonstrating that the 
Angpt1p.R494* mutant allele is functionally null.
At E10.5, whole-embryo CD31 staining showed that the 
majority of p.R494*/Null compound-mutant embryos appeared 
normal, with similar vascular patterning to control littermates. 
However, some embryos appeared smaller with disorganized vas-
culature reminiscent of that reported in ANGPT1-null mice (Fig-
lized protein. However, the critical oligomerization and receptor 
binding domains remained, and the effect of this variant on TEK 
signaling in vivo remained unclear. To investigate this variant pro-
tein in more detail, we therefore used a CRISPR/Cas9 genome- 
editing approach to generate a new mouse line carrying the p.R494* 
mutation (Figure 8, A and B). N1 offspring were born normally and 
genotyped by PCR (Figure 8C) and Sanger sequencing approaches 
(Figure 8D). Heterozygous pups were screened for off-target muta-
tions (Supplemental Figure 8 and Supplemental Table 2) and used 
as founders for all subsequent experiments. Using reverse tran-
scription PCR, Angpt1p.R494* mRNA was detected in E10.5 embryos, 
confirming that the modified transcript is produced and escapes 
NMD (Supplemental Figure 9). As we expected the Angpt1p.R494* 
allele to be loss of function, we additionally generated an Angpt1-
null allele for purposes of comparison. This null allele was creat-
ed by breeding of an Angpt1WBΔE16.5 male with a WT female. Het-
erozygous Angpt1Null/WT mice were born normally and appeared 
healthy. We then generated litters of heterozygous Angpt1p.R494*/WT 
and Angpt1Null/WT mice with WT controls and analyzed SC devel-
opment. At P14, SC exhibited normal morphology and PROX1 
expression in both Angpt1p.R494*/WT and Angpt1Null/WT mice (Figure 
Figure 7. ANGPT1 p.R494* variant protein is trapped within intracellular aggregates. (A and B) Subcellular localization of WT and R494* variant 
ANGPT1. When expressed in NIH 3T3 cells, WT ANGPT1-FLAG detected using anti-FLAG antibody showed a staining pattern consistent with localization 
in the ER (A) and Golgi apparatus (B). However, ANGPT1R494-FLAG was observed aggregated in intracellular vesicles positive for the ER marker PDI but not 
Golgin-97, a marker of the Golgi apparatus. (C) Interaction between WT and ANGPT1R494* within the cell. When coexpressed with untagged ANGPT1R494*, 
FLAG-tagged WT protein detected with anti-FLAG antibody was trapped in intracellular aggregates (white arrows) with untagged ANGPT1R494*. No WT 
ANGPT1-FLAG aggregates are observed in control cells coexpressing untagged WT ANGPT1. Scale bars: 10 μm.
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Discussion
Angpt1;Angpt2 double-knockout mice rapidly develop a severe 
glaucoma phenotype, characterized by complete lack of SC, 
buphthalmos, markedly elevated IOP, and severe damage to the 
neural retina (7). This phenotype is replicated in mice lacking the 
angiopoietin receptor TEK, confirming that signaling through the 
classical angiopoietin/TEK signaling axis is essential for SC for-
mation (7, 8). However, while the importance of TEK signaling is 
clear, specific roles for each angiopoietin ligand have not been pre-
viously described. Here, we identify a critical role for ANGPT1 in 
development of SC and describe 2 PCG patients carrying hetero-
zygous loss-of-function mutations in the ANGPT1 gene.
Mice lacking ANGPT1 alone, or both ANGPT1 and ANGPT2, 
failed to form a normal SC and rapidly developed ocular hyper-
tension. However, as the phenotype of Angpt1;Angpt2 double 
knockouts was more severe than that observed in knockouts of 
Angpt1 alone, we hypothesize that although the proteins have 
canonically opposing roles, compensation between angiopoietin 
ligands was occurring in SC. Unlike the well-defined agonistic 
ure 9B and ref. 12). By E12.5, all Angpt1p.R494*/Null compound mutants 
and Angpt1p.R494*/p.R494* homozygotes were deceased, and some 
were in the process of being reabsorbed (Angpt1p.R494*/Null, 2 of 5; 
Angpt1p.R494*/p.R494*, 5 of 6; Figure 9, B and C). While most embry-
os were degraded and not available for analysis, some had visible 
symmetrical hemorrhage in the region of the jugular lymph sacs.
As homozygous Angpt1p.R494*/p.R494* embryos die in utero, we 
were unable to examine the effect of this variant on SC develop-
ment in the homozygous state. Instead, we crossed heterozygous 
Angpt1p.R494*/WT animals with Angpt1-inducible knockouts to gener-
ate a new Angpt1p.R494*/fl Rosa26rtTA TetOnCre strain (Angpt1p.R494*/Δ 
mice). By administering doxycycline to these mice at E16.5, we 
excised the Angpt1fl allele and obtained viable pups expressing only 
ANGPT1p.R494* (Angpt1p.R494*/ΔE16.5). As predicted, when SC morphol-
ogy was examined at P21, Angpt1p.R494*/ΔE16.5 mice were found to 
have a hypomorphic SC phenotype with reduced PROX1 expres-
sion — duplicating the phenotype observed in Angpt1WBΔE16.5 mice 
and confirming that ANGPT1p.R494* cannot replace WT ANGPT1 in 
SC development (Figure 10).
Figure 8. Generation and analysis 
of Angpt1p.R494* mice. (A) The 
CRISPR/Cas9 system was used to 
generate a novel ANGPT1R494*- 
expressing mouse line. While Arg-
494 is conserved between mice and 
humans, it is encoded by different 
codons in each species. Therefore, 
different genomic DNA modifica-
tions are required for the p.R494* 
substitution in mice and humans. 
(B) Targeting strategy used to 
design guide RNAs. (C) Genotyp-
ing of N1 mice showing positive 
mutants following PCR and HpaII 
digestion. (D) Sanger sequencing 
analysis of a heterozygous founder 
mutant. (E) SC appears normal in 
Angpt1Null/WT and Angpt1p.R494*/WT 
heterozygous mice. In E, n = 3 WT/
WT, 3 Null/WT, and 5 p.R494*/WT 
(SC area) or 3 (PROX1 expression) 
animals per group. Scale bars: 50 
μm; ×20 fields comprise an area of 
65,536 μm2. 
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Here, we have identified the alternate situation in vivo, as 
ANGPT2 compensates for the lack of ANGPT1 in the unique SC 
endothelium. Despite the lack of an apparent SC phenotype in 
Angpt2-knockout eyes, a clear difference was apparent between 
the eyes of Angpt1- and Angpt1;Angpt2-knockout animals. This 
finding suggests a compensatory role for ANGPT2 in the absence 
of the primary TEK ligand ANGPT1. Lacking adequate ANGPT1, 
ANGPT2 provides partial compensation, allowing limited canal 
formation (Figure 11A).
The developmental failure of SC in Angpt1-knockout mice 
appears to occur through 2 separate but related processes: reduced 
sprouting from the LVPs, and decreased proliferation of the vas-
cular sprouts that form SC. Unlike VEGF signaling, which acts 
behavior of ANGPT1, the role of ANGPT2 remains poorly under-
stood. It has been described as a context-dependent TEK agonist/
antagonist or weak agonist, but there is no consensus as to the 
cues mediating signaling activity in different endothelial beds. 
The ligandless receptor TIE (also known as TIE1) (22), integrins 
(23, 24), and level of TEK expression (23) have been proposed 
as factors mediating ANGPT2’s different roles. Classic experi-
ments on the ANGPT1-mediated rescue of intestinal lacteals in 
an Angpt2-knockout model confirm the ability of ANGPT2 to act 
as a TEK agonist in the lymphatic endothelium (14). However, 
this compensation did not occur in the retinal blood vasculature, 
indicating a clear difference between the roles of ANGPT2 in the 
blood and lymphatic endothelium.
Figure 9. Angpt1p.R494* cannot replace 
WT Angpt1 in embryonic development. 
(A) Heterozygous Angpt1p.R494*/WT mice 
were crossed with Angpt1Null/WT animals 
or inbred with Angpt1p.R494*/WT mice to 
generate p.R494*/Null or p.R494*/ 
p.R494* offspring completely lacking WT 
ANGPT1 protein. While Angpt1p.R494*/Null 
pups were observed at normal Mendelian 
ratios early in embryonic development, 
double-mutant and homozygous mutant 
embryos died between E10.5 and E12.5 
and no viable pups were born. (B and C) 
At E10.5, while all embryos were found 
alive, some Angpt1p.R494*/Null double 
mutants appeared smaller than control 
littermates and exhibited disorganized 
vasculature. By E12.5, all double-mutant 
and p.R494* homozygous embryos were 
found deceased (B and C), and some had 
been partially reabsorbed. Interestingly, 
some embryos had a visible hemorrhage 
in the region of the jugular lymph sac 
(white arrows), suggesting a possible 
defect in lymphovenous valve function. 
†Pups found deceased. *No mortality was 
observed between birth and P14. Scale 
bars: 1 mm (B, top panels) and 2 mm (B, 
bottom panels, and C).
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ment with recombinant ANGPT1 is sufficient to cause venous 
enlargement in the microvasculature of the dermis and trachea 
(25), our results indicate that native ANGPT1 signaling in the iri-
docorneal angle is required for proliferation and widening of the 
venous-lymphatic hybrid SC endothelium from a narrow sprout-
ing plexus into its mature form.
Interestingly, although the SC defects we observed are caused 
by loss of an endothelial-specific growth factor pathway, the TM 
of Angpt1-knockout mice was found to be severely hypoplastic, 
suggesting a critical role for SC endothelium in regulation of TM 
development. A similar mechanism is well described in other 
endothelial beds, such as the renal glomerulus, where PDGFB sig-
naling from the glomerular endothelium is critical for recruitment 
of mesangial cells (31).
The importance of ANGPT1 in the development and mainte-
nance of aqueous humor homeostasis is confirmed by the discovery 
of rare ANGPT1 loss-of-function mutations in our cohort of PCG 
patient families. Consistent with the results of our mouse genet-
ics studies, no PCG-associated variants were discovered in the 
ANGPT2 or ANGPT4 genes, emphasizing the role of ANGPT1 as the 
dominant TEK ligand in SC. Interestingly, while both novel ANGPT1 
nonsense mutations we identified have a clear impact on ANGPT1 
function and its ability to interact with the TEK receptor, each has 
a different mechanism. p.Q236* completely lacks the C-terminal 
receptor binding domain, which is required for interaction with 
TEK (19, 20). In addition, the truncated ANGPT1Q236* protein can 
readily form oligomeric complexes through its intact N-terminal 
domain with WT ANGPT1, a process that is critical to the signaling 
function of ANGPT1 (18, 19). We hypothesize that in heterozygous 
PCG patients, any truncated protein that escapes NMD might have 
a dominant-negative function on ANGPT1 signaling.
Compared with p.Q236*, the impact of the p.R494* muta-
tion on ANGPT/TEK signaling was more difficult to predict, as 
the mutant protein lacked only 5 amino acids at the C-terminus, 
located outside of the receptor binding surface. Nevertheless, 
predominantly to encourage endothelial sprouting, ANGPT1- 
mediated TEK activation has been described to have a critical role 
in vascular stability and regulation of venous diameter, and cannot 
directly initiate sprouting angiogenesis (25). However, ANGPT1 
can increase the sprouting angiogenic response to VEGF (26), and 
as VEGF signaling is essential for the initial sprouting in SC devel-
opment (5), our data suggest that ANGPT1 has a similar potentiat-
ing effect in the canal. Angiogenic sprouts leave the blood vascular 
plexuses of the limbus and are drawn into the limbal tissue toward 
the iridocorneal angle, probably by a gradient of VEGF (5, 6). In 
the absence of ANGPT1 this proangiogenic stimulus was reduced, 
blunting the sprouting process. As pre-SC endothelial cells must 
interact with neighboring sprouts in order to consolidate and form 
the mature canal (5), we hypothesize that the reduced sprouting 
observed in Angpt1-knockout mice was directly related to the fail-
ure of canal formation. With fewer sprouts available for interac-
tion, fewer cells find their neighbors to begin the process of canal 
development. It is possible that the infrequent interactions that 
do occur in Angpt1-knockout mice are responsible for the isolat-
ed canal segments we observed, suggesting a direct link between 
efficiency of the initial sprouting process and eventual aqueous 
humor drainage function (Figure 11B).
In addition to the reduction in endothelial sprouts observed in 
the Angpt1 knockout, the failure of the narrow, disorganized pri-
mordial SC to widen into a mature vessel is reminiscent of the role 
ANGPT/TEK signaling plays in venous widening (25). In patients, 
TEK mutations that cause hyperactivation of the receptor lead 
to an extreme version of this effect, resulting in hereditary and 
sporadic venous malformations (27, 28). SC has been described 
as a “hybrid vessel,” incorporating elements of both blood and 
lymphatic vascular physiology (4–7, 29, 30). However, it can per-
haps be most accurately described as a large vein-like structure 
that expresses the lymphatic transcription factor PROX1 in addi-
tion to classical venous markers such as endomucin, CD34, and 
COUP-TFII (Supplemental Figure 11 and refs. 4–6). Just as treat-
Figure 10. Angpt1p.R494* cannot replace WT Angpt1 in SC development. Compared with littermate flox/flox and p.R494*/flox controls, at P21, Angpt1p.R494*/ΔE16.5 
mice exhibited a hypomorphic SC with reduced PROX1 expression resembling that of Angpt1WBΔE16.5 mice. This finding confirms that the Angpt1p.R494* allele 
is functionally null in the context of SC development. n = 5 (flox/flox), 3 (p.R494*/flox and p.R494*/ΔE16.5), and 8 (WBΔE16.5) animals per group.  
**P < 0.01, ***P < 0.001 vs. flox/flox as determined by 1-way ANOVA followed by Bonferroni’s correction. AFU, background subtracted arbitrary fluores-
cence units. Scale bars: 50 μm; ×20 fields comprise an area of 65,536 μm2.
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Although heterozygous Angpt1p.R494*/WT mice did not display 
SC defects, we have previously shown that TEK heterozygosity 
in mice results in comparatively minor defects in SC morphology 
and only slightly elevated IOP. However, in patients, the defect is 
much more severe, leading to PCG with dramatic IOP elevation 
(>10 mmHg), buphthalmos, and optic neuropathy (8). This sug-
gests a greater sensitivity to ANGPT/TEK signaling defects in the 
human eye compared with the mouse, and we hypothesize that 
any defect or haploinsufficiency in ANGPT/TEK signaling has a 
pathogenic effect in human patients with variable expressivity.
The third ANGPT1 variant identified in our PCG cohort, 
p.K249R, is a rare missense allele observed only once, in a South 
Asian individual, in the ExAC exome variant database. Despite the 
strong evolutionary conservation of K249 and its location within 
the critical multimerization domain, we were unable to identify 
defects in oligomerization, secretion, receptor binding ability, or 
downstream signaling by this variant protein using our in vitro 
system. While p.K249R may have an effect on ANGPT1 signaling 
function that was undetected using our system, without additional 
information about disease and genotype segregation in this fam-
ily we cannot exclude the possibility that this patient carries an 
unidentified mutation in another gene responsible for the disease. 
Furthermore, the p.K249R subject identified in our PCG cohort is 
of Kenyan descent, a population that is underrepresented in ExAC 
and other public databases, raising the possibility that p.K249R is 
a population-specific benign variant.
In summary, discovery of pathological ANGPT1 mutations in 
PCG families implicates a second member of the ANGPT/TEK 
signaling axis in glaucoma pathogenesis and underscores the 
importance of this signaling system in the function of the ante-
rior segment of the human eye. Importantly, unlike the known 
PCG-associated genes CYP1B1, LTBP2, FOXC1, and MYOC, the 
ANGPT/TEK pathway offers a number of proteins that might be 
targeted by potential therapies in the future. The range of IOP and 
SC morphological phenotypes observed in mice deficient in TEK 
signaling demonstrates the exquisite balance of signaling events 
these residues are highly evolutionarily conserved, and in silico 
analysis tools predicted that this mutation would strongly desta-
bilize the folded protein. Consistent with these predictions, our in 
vitro studies revealed that ANGPT1R494* was unable to be secreted 
due to its retention within intracellular ER-derived vesicles. When 
coexpressed, WT ANGPT1 was also trapped in these vesicles, 
indicating that, like ANGPT1Q236*, the ANGPT1R494* variant protein 
product may also have a dominant-negative effect on ANGPT sig-
naling in the heterozygous state.
Both p.Q236* and p.R494* variants displayed potential 
dominant-negative effects in our in vitro assays. However, as 
ANGPT1 is essential for development of the embryonic cardiovascu-
lar system, any dominant-negative variant compatible with life must 
have an incomplete effect. In the case of the p.Q236* variant, this 
may be explained by nonsense-mediated decay of the variant tran-
script. Even if the truncated protein was strongly dominant negative, 
we predict that it would be expressed at low levels compared with 
the WT allele in heterozygous patients. However, interindividual 
variability has been reported in NMD efficiency, and this may result 
in variable penetrance of disease in affected patients (32). Similar-
ly, while the p.R494* variant displayed potential dominant-negative 
effects in our in vitro analysis, this effect was minimal or absent in 
vivo. ANGPT1 signaling is essential for embryonic vascular devel-
opment, and Angpt1-null mice die between E9.5 and E12.5 (11, 12). 
However, Angpt1p.R494*/WT heterozygous mice were born normally 
with a normal SC — indicating that sufficient ANGPT/TEK signaling 
was present to allow vascular development. Despite this minimal or 
absent dominant-negative effect, ANGPT1R494* was unable to replace 
WT ANGPT1 in mouse vascular development, and Angpt1p.R494*/Null 
compound mutant or Angpt1p.R494*/p.R494* homozygous mice did not 
survive until birth, dying between E10.5 and E12.5. At E10.5, some 
compound mutant embryos appeared smaller than healthy controls, 
with profoundly disturbed vascular patterning. A similar finding has 
been reported in Angpt1 full-body-knockout mice, confirming that 
Angpt1p.R494*/Null and Angpt1p.R494*/p.R494* mice are functionally analo-
gous to full Angpt1 knockouts.
Figure 11. Defects in ANGPT/TEK signaling 
result in a hypoplastic SC insufficient for 
normal drainage. (A) ANGPT1 is the primary 
TEK ligand in SC development, although 
limited compensation from ANGPT2 is 
possible. (B) Reductions in ANGPT1/
TEK signaling lead to reduced angiogenic 
sprouting from the superficial vascular 
plexus (blue). The sparse sprouts observed 
in Angpt1WBΔE16.5 mice are unable to reach 
their neighbors, interdigitate, and mature 
into a normal SC (green), resulting in irreg-
ular canal formation, inadequate aqueous 
humor drainage, and glaucoma.
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Burrows-Wheeler Aligner (BWA) (http://bio-bwa.sourceforge.net/), 
and duplicates were marked and removed using Picard (http:// 
broadinstitute.github.io/picard/). Single-nucleotide variants and 
small insertions/deletions (indels) were called using Genome Anal-
ysis Toolkit (GATK; Broad Institute) and annotated against RefSeq 
transcripts using ANNOVAR. Variant data were filtered to remove 
synonymous changes, intronic variants more than 10 nucleotides 
from the intron-exon splice site junctions, variants present in the 
ExAC public database (exac.broadinstitute.org) at an allele frequency 
greater than 0.0001, and variants identified in an in-house database 
of 120 control exomes. All exome variants identified in ANGPT1 were 
validated by Sanger sequencing. The ANGPT1 gene was also directly 
Sanger-sequenced in an additional 80 PCG families. Genomic primer 
sequences are provided in Supplemental Table 3.
Design and generation of the ANGPT1R494* mutant mouse line. A 
CRISPR/Cas9 approach was used to generate ANGPT1R494* mice. 
While the protein sequence flanking R494 is conserved in humans and 
mice, R494 is encoded using different codons (Figure 8A). Therefore, 
the genomic mutation used to generate p.R494* mice (c.1477C>T; 
c.1479G>A) is slightly different from that observed in human patient 
family 1 (c.1480C>T). To generate this mutation, a Web-based CRIS-
PR design tool (http://crispr.mit.edu/) was used to select candi-
date guide RNA sequences and scan for possible off-target matches 
throughout the mouse genome. Five candidate single-guide RNA 
(sgRNA) sequences were selected for testing (Supplemental Table 1). 
Selected sgRNAs were cloned into the pX458 vector (Addgene plas-
mid 48138), which expressed SpCas9 in mammalian cells. sgRNA 
activity was validated in mouse Neuro-2a cells (Sigma-Aldrich) before 
injection as previously described (34). For zygote injection, sgRNA 5.1_
sgRNA (Figure 8B) was selected and in vitro–transcribed and purified 
using the MEGAshortscript (AM1354) and MEGAclear kits (AM1908) 
from Ambion (Life Technologies). We injected Cas9 mRNA (GeneArt 
CRISPR Nuclease mRNA catalog A29378), sgRNA, and single-strand-
ed oligonucleotide (chemically synthesized and desalted ssODN; 
Integrated DNA Technologies) into the cytoplasm of single-cell fertil-
ized C57BL/6J zygotes (The Jackson Laboratory). Litters of N1 pups 
were obtained and screened for positive mutants by PCR and Sanger 
sequencing. Genomic DNA was prepared from a tail biopsy using stan-
dard methods, and a PCR product flanking the mutated region was pre-
pared using the following primers: forward 5′-TCCCTTCCTCTGGT-
TACACG-3′, reverse 5′-AAGTGGCGATTCTGTTGACC-3′. Mutants 
were identified by digestion of PCR product using HpaII (Figure 8C), 
and positive individuals were confirmed by Sanger sequencing (Figure 
8D). The MIT CRISPR design tool (http://crispr.mit.edu/) was used to 
obtain a list of possible off-target mutation sites (Supplemental Table 
2), and Sanger sequencing was used to confirm a lack of off-target 
mutations in the 5 strongest matches (Supplemental Figure 8).
Live-animal studies. IOP was measured using a Tonolab rebound 
tonometer (iCare Finland) as previously described (7, 35). Animals 
were restrained in a soft plastic cone, and average IOPs were recorded 
from 3 sets of 6 recordings performed by a blinded technician. Finding 
no difference between left and right eyes, we have reported all IOP 
measurements as single averaged values for each animal.
Whole-mount immunostaining. Eyes were enucleated and immer-
sion-fixed overnight at 4°C (2% formaldehyde in PBS, pH 7.5). After 
fixation, eyes were bisected on the sagittal plane, lens and retina were 
removed, and eyes were stained as whole mounts for confocal micros-
in canalogenesis and highlights the pharmacological potential 
of TEK-modulating therapy in patients with decreased aqueous 
humor outflow or ocular hypertension.
Methods
Generation and breeding of inducible, whole-body angiopoietin-knock-
out mice. Inducible, whole-body deletion of Angpt1 and Angpt2 was 
achieved using a reverse-tetracycline-controlled transactivator (rtTA) 
system driven by the ubiquitously expressed Rosa26 promoter in com-
bination with Angpt1 and Angpt2 floxed alleles as previously described 
(7, 12, 33). Timed, whole-body excision was induced by addition of dox-
ycycline hyclate (0.5%; Sigma-Aldrich) to the drinking water. All mice 
described in this study were given doxycycline at E16.5, and doxycy-
cline treatment was continued until P14 or dissection (if earlier). Flox/
flox littermate mice lacking the rtTA transgene, and thus protected from 
doxycycline-mediated Cre recombinase expression, were used as con-
trols throughout the study. Animals were given unrestricted access to 
standard rodent chow (Harlan; no. 7912) and water. All mice were kept 
on a mixed genetic background, and animals of both sexes were includ-
ed in comparisons. Knockout mice were genotyped by PCR, using the 
following primers: Angpt1fl, forward 5′-CAATGCCAGAGGTTCTTGT-
GAA-3′, reverse 5′-TCAAAGCAACATATCATGTGCA-3′ (WT, 233-bp 
product; Angpt1fl, 328 bp); Angpt1delete, forward 5′-CAATGCCAGAG-
GTTCTTGTGAA-3′, reverse 5′-TGTGAGCAAAACCCCTTTC-3′ (431-
bp product); Angpt2fl, forward 5′-GGGAAACCTCAACACTCCAA-3′, 
reverse 5′-ACACCGGCCTCTAGACACAC-3′ (WT, 224-bp product; 
Angpt2fl, 258 bp); and Angpt2delete, forward 5′-AAGGCGCATAACGA-
TACCAC-3′, reverse 5′-TGAGAACTCTGCAGCCTTGA-3′ (Angpt2fl, 
1,372-bp product; Angpt2delete, 426 bp).
Real-time PCR. Angpt1 and Angpt2 deletion was confirmed using 
quantitative, real-time PCR. Lung tissue from whole-body knockout 
mice was collected, and total RNA was isolated using Trizol reagent 
(Life Technologies). cDNA was then generated using the iScript 
kit (Bio-Rad Laboratories), and real-time PCR was performed on 
an ABI 7500 thermocycler (Applied Biosystems) using iTaq SYBR 
Green master mix (Bio-Rad Laboratories) and the following prim-
ers: Gapdh, forward 5′-AAGGTCATCCCAGAGCTGAA-3′, reverse 
5′-CTGCTTCACCACCTTCTTGA-3′; Angpt1, forward 5′-GGGGG-
AGGTTGGACAGTAA-3′, reverse 5′-CATCAGCTCAATCCTCAGC- 
3′; Angpt2, forward 5′-GATCTTCCTCCAGCCCCTAC-3′, reverse 
5′-TTTGTGCTGCTGTCTGGTTC-3′.
Human study participants. PCG was defined by the following char-
acteristics: (a) age of onset less than 3 years, (b) increased corneal 
diameter greater than 10 mm accompanied by corneal edema and/or 
Haab’s striae, and (c) IOP greater than 21 mmHg and/or optic nerve 
cupping greater than 0.4. Any patient with other ocular abnormali-
ties or systemic conditions, other than iris stromal hypoplasia, was 
excluded from the study. Subjects and their families were recruited 
from multiple international centers, each of which had received study 
approval from its respective IRB. Our studies adhered to the tenets of 
the Declaration of Helsinki and were compliant with the Health Insur-
ance Portability and Accountability Act (HIPAA).
Exome and Sanger sequencing. Exome sequencing of 135 PCG 
families was performed using Nimblegen EZ version 3 (Roche) or 
SureSelect V4/V5 (Agilent) capture kits, and 2 × 100-bp paired-
end sequencing on a HiSeq2500 platform (Illumina). Reads were 
aligned to the human reference genome (GRCh37/hg19) using the 
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Reporter mouse lines. Angpt1GFP (Angpt1tm1.1Sjm/J) mice were a gift from 
Sean Morrison (University of Texas Southwestern Medical Center, 
Dallas, Texas, USA) and were generated and genotyped as previously 
described (39). Adult eyes were collected, fixed as described above, and 
embedded in OCT media for cryosectioning. Ten-micrometer cryosec-
tions were collected, blocked as described above, and stained using anti-
GFP (Thermo Fisher Scientific; PA5-22688, 1:500) and anti-endomucin 
(Abcam; Ab106100; 1:250) antibodies. Angpt2LacZ (Angpt2tm1Gdy) mice 
were generated and genotyped as previously described (14). After col-
lection, eyes were briefly fixed (0.2% glutaraldehyde in PBS, pH 7.4), 
washed (TBS containing 0.05% Tween-20), and incubated overnight in 
1 mg/ml X-gal staining solution at 37°C. After staining, eyes were fixed 
overnight in 10% formalin before paraffin embedding and sectioning 
using standard methods. Prox1-tdTomato [Tg(Prox1-tdTomato)] mice 
were a gift from Guillermo Oliver (Northwestern University Feinberg 
School of Medicine, Chicago, Illinois, USA) and were genotyped as pre-
viously described (40). Adult eyes were used for whole-mount immu-
nostaining as described above.
In vitro assays. HEK293 and NIH 3T3 cells were gifts from Tomoko 
Hayashida (Northwestern University Feinberg School of Medicine). 
HUVEC-C cells (CRL-1730) were purchased from the ATCC. ANGPT1 
expression constructs were created by cloning of full-length ANGPT1 
cDNA into the pcDNA3 vector. 3′-FLAG (DYKDDDK) or -HA (YPYD-
VPDYA) tag sequences were introduced replacing the stop codon in 
frame using standard cloning methods (Supplemental Figure 7). To 
introduce mutations into this WT ANGPT1 vector, site-directed muta-
genesis was performed using the PrimeSTAR Max kit (Takara Bio Inc.) 
to generate variant ANGPT1-expressing vectors.
Western blot analysis. Intracellular and secreted ANGPT1 protein 
abundance was determined by Western blot. Plasmid vectors con-
taining variant or WT ANGPT1 were transfected into subconfluent 
HEK293 cells seeded in 6-well culture dishes using Lipofectamine 
2000 reagent (Life Technologies). The following day, the cells were 
transferred to serum-free media and incubated for 24 hours before 
harvesting by lysis in 2× Laemmli sample buffer. Conditioned growth 
media were collected and concentrated using a size-filter exclusion 
column (Amicon Ultra; 10 kDa; Merck Millipore). Concentrated 
media were then diluted with sample buffer. For reducing conditions, 
β-mercaptoethanol was added. Samples were separated by SDS-PAGE 
and transferred to PVDF membranes using standard procedures 
before protein abundance was detected using mouse anti–human 
ANGPT1 (R&D Systems; MAB9231; 1:500) and mouse anti–FLAG M2 
(Sigma-Aldrich; F3165; 1:5,000) antibodies. For loading control of cell 
lysates, α-tubulin was detected using anti–α-tubulin antibody (clone 
DM1A, catalog 32293; Santa Cruz Biotechnology; 1:2,000). For load-
ing control of conditioned media, membranes were stained using Gel-
Code Blue reagent (Bio-Rad Laboratories). For the proteosomal inhib-
itor study, transfected HEK293 cells were treated with 1 μM MG132 
(Enzo Life Sciences) or DMSO for 24 hours.
TEK-Fc pulldown assay. The interaction of ANGPT1 and TEK 
receptor was tested as follows. WT and mutant ANGPT1 proteins 
were produced by transfection of HEK293 cells with expression vec-
tors encoding FLAG-tagged variant proteins as described above. Con-
ditioned medium was collected and mixed with 1 μg of recombinant 
human TEK2-Fc protein (Ala23-Lys745; R&D Systems; 313-TI-100) 
and incubated for 1 hour. Then, protein A beads blocked with 5% BSA 
solution were added to the medium to capture TIE2-Fc/ANGPT1 
copy. Retinal ganglion cells were visualized in retina flat mounts as 
previously described (36).
Fixed tissues were blocked overnight at 4°C (5% donkey serum, 
2.5% BSA, 0.5% Triton X-100 in TBS, pH 7.5). After blocking, sam-
ples were incubated overnight in appropriate blocking buffer–diluted 
primary antibodies. The following primary antibodies and dilutions 
were used: rat anti–mouse CD31 (BD Pharmingen; 550274; 1:100), 
goat anti–human PROX1 (R&D Systems; AF2727; 1:250), rabbit 
anti–mouse Ki67 (Thermo Fisher Scientific; MA5-14520; 1:250), rat 
anti–mouse endomucin (Abcam; AB106100; 1:250), goat anti–mouse 
LYVE-1 (R&D Systems; AF2125; 1:250), rat anti–mouse CD34 (BD 
Pharmingen; 553731; 1:500), rabbit anti–human vWF (Dako; A0082; 
1:1,000), mouse anti-Brn3a (Millipore; MAB1585; 1:400), goat 
anti-Brn3b (Santa Cruz Biotechnology; sc-6026; 1:1,000). Eyes were 
washed at room temperature (6 × 1 hour, 0.05% Tween-20 in TBS, 
pH 7.5) and returned to 4°C for overnight incubation in appropriate 
Alexa Fluor–labeled secondary antibodies (Invitrogen). After stain-
ing, tissues were washed a second time before trimming and mount-
ing. Tissues were imaged using a Nikon A1R confocal microscope 
at the Center for Advanced Microscopy of Northwestern University. 
Images of SC development were captured using a ×20 objective with 
a numerical aperture of 0.75 to collect 10-image Z-stacks with a step 
size of 1.67 μm and a pinhole of 1.2 Airy units. Images are shown in 
the figures as maximum-intensity projections generated using Fiji 
software (37). Image quantification of whole-mounted limbal regions 
was performed by capturing of 3 images at intervals from each eye. 
Measurements from these replicates were averaged to obtain final 
values for each animal. Large-field images of adult SC morphology 
were obtained by stitching of images captured using the same ×20 
objective and a fully opened 150-μm pinhole.
Whole-mount embryo analysis. Embryos from Angpt1p.R494* mutant 
mice were collected at E10.5 and fixed (2% formaldehyde in PBS, pH 
7.5, overnight at 4°C). Fixed embryos were then embedded in acryl-
amide hydrogel (4% acrylamide, 0.25% bis-acrylamide in PBS, pH 
7.5) containing a thermal initiator [0.25%; Wako Chemicals; 2,2-AZO-
BISY2-(2-IMIDAZOLAN-2)]. After overnight incubation at 4°C to 
allow acrylamide penetration, samples were moved to 37°C for 4 hours 
to polymerize the hydrogel. Samples were then blocked and stained 
with anti-CD31 antibodies as described above and mounted using sor-
bitol-based refractive index matching solution (70% sorbitol (w/v) in 
0.02 M phosphate buffer pH 7.5 containing 0.01% sodium azide) (36). 
Mounted embryos were imaged using a Nikon A1R confocal micro-
scope. Stitched 10-image Z-stacks are presented in the figures as max-
imum-intensity projections. Larger embryos (>E10.5) were collected 
and imaged using a Panasonic Lumix digital camera.
TM analysis. Semithin sections of the iridocorneal angle and 
TM were prepared and stained as previously described (8, 38). 
For α-smooth muscle actin staining, enucleated eyes were immer-
sion-fixed as described above before dehydration and paraffin embed-
ding according to standard methods. Five-micrometer sections were 
prepared and dewaxed, and antigen retrieval was performed (10 mM 
Tris, 1 mM EDTA, 0.05% Tween-20, pH 9, autoclaved 121°C 30-min-
ute liquid cycle) before blocking (5% donkey serum, 2.5% BSA, 0.5% 
Triton X-100 in TBS, pH 7.5, 1 hour at room temperature) and over-
night incubation with FITC-conjugated primary antibody (Sigma- 
Aldrich; F3777; 1:250). After staining, slides were mounted and 
imaged on a Nikon C2+ confocal microscope.
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University of São Paulo. Written informed consent for study participa-
tion was obtained from the subjects or the subjects’ parents.
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complexes. Samples were washed with TBS with 0.1% Triton X-100 
and eluted with Laemmli sample buffer containing β-mercaptoetha-
nol. The presence of ANGPT1-TEK-Fc complexes was determined by 
Western blotting using antibodies against FLAG and human IgG.
HUVEC stimulation assay. The ability of mutant ANGPT1 proteins 
to activate TEK downstream signaling was performed as follows. Con-
ditioned media from HEK293 cells transfected with WT or mutant 
ANGPT1 proteins were prepared as described above for the TEK-Fc 
pulldown assay. After harvesting of conditioned medium, it was concen-
trated using a size-exclusion column (Amicon Ultra; 10 kDa). HUVECs 
were stimulated with concentrated conditioned media for 30 minutes at 
37°C and then harvested by lysis in 2× Laemmli sample buffer.
Immunocytochemistry. Intracellular ANGPT1 distribution was 
determined by immunocytochemistry. NIH 3T3 cells were seeded onto 
coverslips coated with 0.1% poly-l-lysine (Sigma-Aldrich). Subcon-
fluent cells were transfected with variant or WT ANGPT1-expressing 
vectors using Lipofectamine 2000. Transfected cells were fixed (2% 
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(0.1% Triton X-100 in PBS, pH 7.5, 10 minutes), and blocked (1% BSA 
in PBS, pH 7.5, 30 minutes) before staining. Cells were then incubated 
with primary antibodies (mouse anti–human ANGPT1; R&D Systems; 
MAB9231; 1:100; and mouse anti-FLAG; Sigma-Aldrich; F3165; 1:100) 
and Alexa Fluor 488–conjugated phalloidin (Invitrogen, Thermo Fish-
er Scientific) overnight at 4°C before appropriate Alexa Fluor–conjugat-
ed secondary antibodies were used to detect FLAG-labeled or native 
ANGPT1 protein in the cells. DAPI was used for staining of cell nuclei. 
Images were obtained using a Nikon C2+ confocal microscope. Anti-
bodies against Golgin-97 (CST, D8P2K) and PDI (CST, C81H6) were 
used to determine the subcellular distribution of the ANGPT1 proteins.
Statistics. Statistical analysis was performed using Prism 5 soft-
ware (GraphPad). Throughout the text, values are reported as means 
± SEM. Indicated P values were obtained using a 2-tailed Student’s t 
test or ANOVA followed by use of Bonferroni’s method for multiple 
comparisons where appropriate. Comparisons of groups with differing 
sample sizes were made with Welch’s unequal variances t test. P values 
of less than 0.05 were considered statistically significant.
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